QuantLogix ← MRNA scorecard
📅 MRNA Earnings Preview
MRNA
Next report (est.)
10/30/2026
Countdown
3 days
EPS growth YoY
+7.5%
Revenue growth YoY
+2.1%
Implied vs actual — last 8 reports
ReportOptions impliedActual moveMarket was
07/31/2026 ±5.1% -5.3% under-priced
05/01/2026 ±5.7% -1.2% over-priced
02/20/2026 ±7.4% +0.3% over-priced
11/06/2025 ±9.0% +3.3% over-priced
08/01/2025 ±5.7% -6.6% under-priced
05/01/2025 ±4.2% -5.3% under-priced
02/21/2025 ±9.8% +5.3% over-priced
11/07/2024 ±4.4% -3.0% over-priced
Across these reports, options implied an average ±6.4% move vs an actual average of 3.8% — the stock stayed inside the implied band 63% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q2 FY2026 $-1.97 $145M $-782M
Q1 FY2026 $-3.40 $389M $-1.3B
Q4 FY2025 — $678M $-826M
Q3 FY2025 $-0.51 $1.0B $-200M
Analyst posture
Buy / Strong Buy
11
Hold
16
Sell
4
Strong upward revisions — 10 net (vs 13 prior)
Live 5-factor engine read: Buy · 82/100 Full scorecard →
Get alerted before every MRNA report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on MRNA before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

MRNA (MRNA) reports in 3 days, with the next report estimated for 10/30/2026. Across the last 8 reports, options priced an average ±6.4% earnings move while the stock actually moved 3.8% on average — the market has been roughly fair on MRNA's earnings risk. Fundamentals into the print: EPS up 7.5% year-over-year, revenue up 2.1%. QuantLogix's live 5-factor engine currently reads MRNA as a buy at 82/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →